Skip to main content

Neoadjuvant Head and Neck Squamous Cell Carcinoma HexAgon-HN

Status: Completed

Study Details

View study details on clinicaltrials.gov.

Locations

  • Sacramento

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (HexAgon-HN

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20.

Nitin Rohatgi
Nitin Rohatgi
Principal investigator
View Profile

Co-investigator

Jasdeepa Nagi

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?